The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Several cases of hepatocellular carcinomas and cervical squamous cell carcinomas exhibited moderate to strong cytoplasmic and nuclear staining while ductal breast carcinomas and malignant carcinoids displayed cytoplasmic positivity. Cases of urothelial cancers showed moderate to strong nuclear positivity. Remaining malignant cells were in general weakly stained or negative.
Most malignant melanomas, thyroid and lung cancers as well as cases of ovarian and endometrial cancers showed weak to moderate nuclear and cytoplasmic positivity. Remaining malignant cells were generally negative.
Validation
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
